Reportlinker.com

Reportlinker.com

June 27, 2008 16:25 ET

Learn about the World Ophthalmic Pharmaceutical Drugs Market

LONDON, UNITED KINGDOM--(Marketwire - June 27, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

World Ophthalmic Pharmaceutical Drugs Market

http://www.reportlinker.com/p090570/World-Ophthalmic-Pharmaceutical-Drugs-Market.html

This report analyzes the worldwide markets for Opthalmic Pharmaceutical Drugs in US$ Million. The major therapeutic categories analyzed are Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 96 companies including many key and niche players worldwide such as Akorn, Inc., Alcon Eye Care, Inc., Allergan, Inc., Alimera Sciences, Inc., Bausch & Lomb, Inc., Genvec, Inc., GlaxoSmithKline Plc, Inspire Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Ophthalmics, Opko Health, Inc., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., QLT, Inc., Santen Pharmaceutical Co., and Santen Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.


OPHTHALMIC PHARMACEUTICAL DRUGS MCP-1490 
A GLOBAL STRATEGIC BUSINESS REPORT 


CONTENTS 


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 
Study Reliability and Reporting Limitations I-1 
Disclaimers I-2 
Data Interpretation & Reporting Level I-2 
Quantitative Techniques & Analytics I-2 
Product Definitions and Scope of Study I-3 

II. EXECUTIVE SUMMARY 

1. Industry Overview II-1 
A Curtain Raiser II-1 
Drugs Developed in the Recent Past II-1 
What the Future Holds in Store? II-2 
Where Does the Opportunity Lie? II-2 
In the Shifting Demographics II-2 
Which Disease Segment Offers Abundant Opportunities for R&D 
Initiatives II-3 
Leading Companies & Their Areas of Research Interest/Focus II-4 
Business Opportunities in Ophthalmology: A Fact Sheet II-4 
Impediments in Picking the Ripe & Low Hanging Opportunities II-4 
Low Patient Compliance II-4 
What's the Antidote to Low Patient Compliance? II-5 
Innovation in Ophthalmic Pharmaceuticals: How Does It Help 
Patients? II-5 
An Unequivocal Discussion About Ocular Drug Design and Delivery II-6 
Why Understanding of the Metabolic Activity of the Eye is 
Important? II-6 
Pitfalls of Traditional Ocular Treatment II-7 
Ophthalmic Drug Delivery: A Recapitulation of Facts II-7 
Antidotes to Low Delivery of Ocular Drugs & High Side Effects II-8 
Prodrug II-9 
Soft Drugs (SDs) II-9 
Soft Corticosteroids II-9 
Drug Penetration Enhancers II-10 
Chitosan Based Drugs & Drug Delivery Systems II-10 
How Chitosan is used to Improve Ocular Drug Retention On 
the Eye's Surface? II-10 
The Future of Ophthalmic Drug Delivery II-11 
A Straight Talk About Ophthalmic Drug Delivery Technologies II-11 
High Flying Expectations of Blistering Pace of Drug 
Development Grounded II-11 
First Generation Advancements Made in Ocular Drugs II-12 
Second Generation Advancements Made in Ocular Drugs II-12 
Limiting Factors II-13 

2. Market Dynamics II-14 
Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty II-14 
Ophthalmic Inserts Flaunt the Potential to Eclipse the 
Popularity of Eye Drops II-14 
Rising Incidences of Glaucoma: A Business Case for Ophthalmic 
Drugs II-15 
Aging Population & Environmental Factors Drive Growth II-15 
Increase in Health Care Spending II-15 
Opportunities Abound in the Developing Countries II-16 
Innovative Products Lend Traction to Growth II-16 
Reimbursements: "Under the Umbrella" II-16 
Pricing Statistics On Select Ophthalmic Drugs in the United 
States for the Year 2006 II-17 
Price Changes for Select Ophthalmic Drugs in the Year 2005 II-18 

3. An Overview of Ophthalmic Drugs II-19 
Anti Viral Drugs II-19 
Adenoviral Infections II-19 
Herpes Simplex Virus II-19 
Herpes Zoster (Varicella Zoster Disease) II-19 
Corticosteroids II-19 
Loteprednol II-20 
Prednisolone II-20 
Dexamethasone II-21 
Fluorometholones II-21 
Fluorometholone Alcohol II-21 
Fluorometholone Acetate II-21 
Rimexolone II-22 
Clinical Efficacy of Steroids II-22 
Topical Corticosteroid Drugs II-22 
Tapering of Steroid Intake II-23 
Non-Steroids Anti Inflammatory Drugs (NSAID) II-23 
Use of Topical NSAIDs II-24 
Topical & Systemic NSAIDs II-24 
Ketorolac: A Potent NSAID II-24 
Non-Steroidal Anti-Inflammatory Drugs II-24 
Antibiotics II-25 
Sodium Sulfacetamide II-25 
Sulfisoxazole II-25 
Bacitracin II-26 
Bacitracin and Polymyxin B: A Powerful Duo II-26 
Bacitracin, Polymyxin B and Neomycin: Three To Tango II-26 
Trimethoprim with Polymyxin B II-26 
Chloramphenicol II-27 
Erythromycin II-27 
Gentamicin and Tobramycin II-27 
Fluoroquinolones II-28 
Types of Fluoroquinolones II-28 
Ciprofloxacin II-28 
Gatifloxacin II-28 
Levofloxacin II-28 
Moxifloxacin II-29 
Ofloxacin II-29 
Topical Antibiotic Drugs II-29 
Ophthalmic Antihistamines II-30 
Azelastine II-30 
Emedastine II-30 
Epinastine II-30 
Ketotifen II-30 
Olopatadine II-30 
Ophthalmic Mast-Cell Stabilizers II-31 
Cromolyn II-31 
Nedocromil Sodium II-31 
Pemirolast II-31 
Drugs to Treat Glaucoma II-31 
Beta-Adrenergic Blockers or "Beta Blockers" II-31 
Timolol II-32 
Levobunolol II-32 
Carteolol II-32 
Metipranolol II-32 
Betaxolol II-33 
Alpha-Adrenergic Agonists II-33 
Carbonic Anhydrase Inhibitors II-33 
Acetazolamide II-34 
Dorzolamide II-34 
Acetazolamide & Dorzolamide: How Good Is the Combo? II-34 
Miotics II-34 
Prostaglandins II-34 
Mydriatics & Cycloplegics II-35 
Side Effects II-35 
Over-The-Counter (OTC) Ophthalmic Preparations II-36 
Artificial Tears II-36 
Lubricating Ointments II-36 
Mast Cell Stabilizers II-36 
Antihistamines II-37 
Phenylephrine II-37 
Naphazoline II-37 
Xylometazoline II-37 
Astringents II-37 
Over-The-Counter Ophthalmic Preparations II-38 
A Directory Listing of Major Ophthalmic Pharmaceutical Drugs II-39 
Formulary Anti- Glaucoma Drugs II-39 
Non-Formulary Anti- Glaucoma Drugs II-40 
Formulary Topical Anti-Glaucoma Drugs II-40 
Formulary Ophthalmic Antiinfective/Corticosteroids Drugs II-41 
Non-Formulary Ophthalmic Antiinfective/ Corticosteroids Drugs II-41 
Formulary Ophthalmic Corticosteroid Drugs II-42 
Non-Formulary Ophthalmic Corticosteroid Drugs II-42 
Formulary Ophthalmic Topical Antibacterial Drugs II-43 
Non-Formulary Ophthalmic Topical Antibacterial Drugs II-44 
Formulary Ophthalmic Topical Antiviral Drugs II-44 
Other Ophthalmic Formulary Drugs II-44 
Other Ophthalmic Non-Formulary Drugs II-45 
New Drugs In the Pipeline II-47 

4. Ophthalmic Disorders: A Freeze Frame II-48 
The Human Eye: A Remarkable & Intriguing Organ of Sight II-48 
The Outer Layer II-48 
The Middle Layer II-48 
The Inner Layer II-49 
Common Ophthalmic Disorders: An Exposition II-49 
Cataract II-49 
Causes II-49 
Types of Cataract II-50 
Treatment Strategies II-50 
How Widespread is the Disease? II-51 
Glaucoma II-51 
Who's At Risk? II-51 
Types of Glaucoma II-52 
Primary Open Angle Glaucoma (POAG) II-52 
Acute Angle-Closure Glaucoma (AACG) II-52 
Congenital Glaucoma II-52 
Secondary Glaucoma II-53 
Treatment Strategies II-53 
Anti- Glaucoma Ophthalmic Drugs II-54 
How Widespread is the Disease? II-54 
Table 1: Prevalence of Glaucoma in the World: Year 1999 and 
2006 A Comparison (In 000 Individuals) (includes 
corresponding Graph/Chart) II-55 
Is Marijuana A Potential Cure? II-56 
Age-Related Macular Degeneration (AMD) II-56 
Types of AMD II-56 
Dry AMD (Non-Neovascular) II-56 
Wet AMD (Neovascular) II-56 
Causes II-57 
Treatment Strategies II-57 
Nutrition & AMD II-58 
Diabetic Retinopathy II-58 
Treatment Strategies II-58 
How Widespread is the Disease? II-59 
Ocular Allergies II-59 
Treatment Strategies II-59 
Immunotherapy: A Popular Anti-Allergy Treatment Approach II-60 
Ocular Inflammation: A Symptom of Ocular Allergies II-60 
How Can Allergies Be Prevented? II-61 
Conjunctivitis (Pink Eye) II-61 
Types of Conjunctivitis II-62 
Pathogenesis II-62 
Treatment Strategies II-62 
Keratitis II-63 
Types of Keratitis II-63 
Treatment Strategies II-64 
Dry Eye II-64 
Why Are Tears So Crucial for Normal Eye Health? II-65 
What Causes Dry Eye? II-65 
Treatment Strategies II-65 
Refractive Errors II-66 
Causes for Refractive error II-66 
Treatment for Refractive Errors II-66 
Cost of Treatment II-67 
Factors contributing to the Difference in Surgery Costs II-67 

5. FDA Regulations and Approvals II-68 
Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial II-68 
Alimera Conducts Phase III Medidur Trial II-68 
ISTA Pharmaceuticals Files NDA for Xibrom(tm) QD II-68 
AzaSite Receives FDA Approval II-68 
Alimera Sciences Receives FDA Approval II-69 
Alcon Receives Approval for Vegamox(tm) Ophthalmic Solution in Japan II-69 
Alcon Receives Marketing Approval for Patanol(r) in Japan II-69 
Allergan Receives FDA Approval for Lumigan(r) II-69 
Allergan's Ganfort(r) Receives Pan European License II-69 
Pfizer Receives Approval from EC to Market Macugen(r) II-70 
Akorn Gets Nod for Conducting Clinical Trial of AK-1015 II-70 
Genentech 's Lucentis Receives FDA Approval II-70 
MacuSight Receives FDA Approval for IND Application of Sirolimus II-70 
Sami Labs Receives Approval for Ocufors II-70 
Toyamo and Nidek Obtain Manufacturing Approval for Quinolone 
Ophthalmic Solutions II-70 
Alcon's NEVANAC Receives FDA Approval II-71 
Fougera Obtains Approval for MetroGel(r) II-71 
Allergan's Alphagan P Receives FDA Approval II-71 
Santen Obtains Approval for Manufacturing and Marketing PAPILOCK II-71 
Alcon Receives FDA Approval for Adding Susceptible Pathogens 
to VIGAMOX II-71 
BOL Receives FDA Approval for Ofloxacin II-71 
Hi-Tech Pharmacal Receives FDA Clearance for Ofloxacin 
Ophthalmic Solution II-72 
Vision Blue and DORC International Receives FDA Approval for 
Trypan Blue II-72 
Pfizer Receives FDA Nod for Macugen(r) II-72 
Bausch & Lomb Bags FDA Approval for its Zylet(tm) II-72 
Alcon Receives Approval for Olopatadine (Patanol) II-72 
Pharmacia Receives FDA Approval for Latanoprost Ophthalmic 
Solution II-72 
US FDA Approves Allergan's New Acular LS 0.4% for Ocular Pain 
Reduction II-73 
Allergan Obtains FDA Approval for Zymar II-73 

6. Product Innovations/Introductions II-74 
Inspire Pharmaceuticals Rolls Out AzaSite(tm) for Ocular Infections II-74 
Reckitt Benckiser Launches Two Eye Care Products II-74 
Alcon Launches DUOTRAV for Glaucoma Treatment II-74 
Rohto Pharmaceutical Launches Switch OTC Ophthalmic Drug II-74 
Indoco Remedies to Launch Ophthalmic Drugs in America II-74 
Akorn Launches Ophthalmic Drug Products II-74 
AlphaRx Formulates the Ophthalmic Product, Binoxan(tm) II-75 
Alimera Sciences Introduces Online Consumer Ordering Facility II-75 
Fougera Adds Two Novel Products to its Ophthalmic Product Line II-75 
Micro Vision Launches Anti-Glaucoma Drugs II-75 
ISTA Pharmaceuticals Launches Istalol for Glaucoma Treatment 
in the US II-75 
Falcon Unveils Trifluridine Ophthalmic Solution, 1% II-75 
Alimera Sciences Unveils Soothe(tm) Emollient Eye Drops II-75 
Novartis Introduces Zaditen in Japan II-76 
Falcon Releases Brimonidine Tartrate Ophthalmic Solution, 0.2% II-76 
Taiwanese Researchers Introduces Thermosensitive Ophthalmic Drop II-76 
Alcon Introduces Systane Lubricant Eye Drops II-76 
Allergan Releases Restasis for Dry Eye Treatment II-76 
Biosyntrx Launches BioTears II-76 
Novartis to Introduce Pirenzepine Ophthalmic Gel II-76 

7. Recent Industry Activity II-77 
Bausch & Lomb Acquires IOL Maker, Eyeonics II-77 
Akorn Inks Manufacture &Supply Agreement for Ophthalmic Solution II-77 
CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb II-77 
Genaera Corporation Quits Evizon Clinical Trials II-77 
Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF) 
Aptamer Program II-77 
Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs II-77 
Bausch & Lomb Acquire Soothe Products from Alimera II-78 
Froptix, Acuity, eXegenics Merge to Form Opko Corporation II-78 
Alimera, Emory Collaborate Over Potential Ophthalmic 
Treatments Using Novel Antioxidants II-78 
Santen Signs Agreement with Vistakon Pharmaceuticals for US 
Launch of Iquix(r) II-79 
Inspire Pharmaceuticals Rolls Out AzaSite(tm) for Ocular Infections II-79 
QLT Takes Over Forsight Newco II, Inc II-79 
Phase IV Clinical Trials Of Macugen(r) II-79 
Results Of Phase II Clinical Trials - Macugen(r) II-79 
Macugen(r) Receives European Regulatory Approval II-80 
Bausch & Lomb Purchases OTC Allergy Drugs of Alimera II-80 
Phase II Trial of Acuity Pharmaceutical's Bevasiranib II-80 
Advanced Refractive Technologies Acquires a Subsidiary of UTEK 
Corporation II-80 
Sirion Therapeutics Acquires Sytera II-81 
Teva Pharmaceuticals Acquires Ivax II-81 
Alcon Enters into an Agreement with Amgen II-81 
QLT Signs an Agreement with Retinagenix II-81 
NicOx Enters into Licensing Agreement with Pfizer II-81 
OccuLogix Signs Agreement to Acquire SOLX II-81 
ISTA Receives License from Senju for Allergy Treatments II-82 
Acuity Receives License for Nchlorotaurine II-82 
Akorn and AVR Enter into Commercial Manufacturing & Supply 
Agreement II-82 
Lantibio Signs Agreement with TRB Chemedica II-82 
Argentis and Southern College of Optometry Enter into Agreement II-82 
Bausch & Lomb Enters into Marketing Agreement with Novartis II-82 
Santen Pharmaceuticals and Ube Industries to Develop Glaucoma 
Therapy Jointly II-82 
Santen Pharmaceutical and CytoPathfinder Signs an Agreement II-83 
Kalypsys Inks an Agreement with Alcon, Inc II-83 
Combination RX Enters into a Collaboration Agreement with Fovea II-83 
Par Pharmaceutical Joins Force with Spectrum Pharmaceuticals II-83 
Isotechnika Sells Eye Drug Rights to Lux Biosciences II-83 
Alimera Sciences Collaborates With CYNACON II-83 
Novartis Inks an In-Licensing Agreement with Otsuka II-84 
Alimera Sciences Commences Phase III Trials for Medidur(tm) II-84 
SurModics Acquires InnoRx II-84 
Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical 
Group II-84 
OSI Pharmaceuticals Takes Over Eyetech Pharmaceuticals II-84 
Pfizer Acquires Angiosyn II-85 
Bausch & Lomb Collaborates with PTC Therapeutics II-85 
AMRI Enters into Research Collaboration with Alcon II-85 
Bausch & Lomb Bags License from Cephalon II-85 
PediaMed and Allergan Sign a Co-Promotion Agreement II-85 
SurModics Bags Option to Acquire Exclusive Rights from Rutgers 
University II-85 
Sankyo Co. and Santen Pharmaceutical Sign Agreement II-85 
Acuity Pharmaceuticals Enters into Agreement with Intradigm 
Corporation II-86 
Apotex Inks Marketing Agreement with Akorn II-86 
Novartis Enters into an Agreement with Senju Pharmaceutical II-86 
Novartis Strikes a Licensing Deal with Otsuka Pharmaceutical II-86 
Custom RX recalls Trypan Blue 0.06% Ophthalmic Solution II-86 
AMO Takes Over VISX II-86 
Advanced Medical Optics Acquires Ophthalmic Surgical Business 
of Pfizer II-86 
Santen to Take Over Marketing Rights of Rescula from R-Tech Ueno II-87 
Alimera Sciences Inks Co-promotion Agreement with VISTAKON 
Pharmaceuticals II-87 
Akorn Inks a Purchase and Supply Agreement with FDC II-87 
ISTA Pharmaceuticals Receives Marketing License From Senju 
Pharmaceuticals II-87 
Pfizer Inc Acquires Pharmacia Corp II-87 
Allergan Takes Over Oculex Pharmaceuticals II-87 
Allergan Enters into an Agreement with Acadia II-87 

8. Focus on Select Global Players II-88 
Akorn, Inc. (USA) II-88 
Alcon Eye Care, Inc. (USA) II-88 
Allergan, Inc. (USA) II-89 
Alimera Sciences, Inc. (USA) II-90 
Bausch & Lomb, Inc. (USA) II-90 
Genvec, Inc. (USA) II-91 
GlaxoSmithKline Plc (UK) II-91 
Inspire Pharmaceuticals, Inc. (USA) II-91 
ISTA Pharmaceuticals, Inc. (USA) II-91 
Merck & Co., Inc. (USA) II-92 
Novartis Ophthalmics (Canada) II-92 
Opko Health, Inc (USA) II-93 
Otsuka Pharmaceutical Co., Ltd. (Japan) II-93 
Pfizer Inc. (USA) II-93 
QLT, Inc. (Canada) II-93 
Santen Pharmaceutical Co. (Japan) II-94 
Santen Inc. (USA) II-94 

9. Global Market Perspective II-95 
Table 2: World Recent Past, Current and Future Analysis for 
Ophthalmic Pharmaceutical Drugs by Geographic Region - US, 
Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin 
America and Rest of World Markets Independently Analyzed with 
Annual Sales Figures in US$ Million for Years 2000 through 
2010 (includes corresponding Graph/Chart) II-95 

Table 3: World Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Geographic Region - US, Canada, Japan, 
Europe, Asia-Pacific (excluding Japan), Latin America and Rest 
of World Markets Independently Analyzed with Annual Sales 
Figures in US$ Million for Years 2011 through 2015 (includes 
corresponding Graph/Chart) II-96 

Table 4: World 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Geographic Region - Percentage 
Breakdown of Dollar Sales for US, Canada, Japan, Europe, 
Asia-Pacific (excluding Japan), Latin America and Rest of 
World Markets for Years 2003, 2008 and 2012 (includes 
corresponding Graph/Chart) II-97 

Table 5: World Recent Past, Current and Future Analysis for 
Glaucoma by Geographic Region - US, Canada, Japan, Europe, 
Asia-Pacific (excluding Japan), Latin America and Rest of 
World Markets Independently Analyzed with Annual Sales Figures 
in US$ Million for Years 2000 through 2010 (includes 
corresponding Graph/Chart) II-98 

Table 6: World Long-term Projections for Glaucoma by 
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific 
(excluding Japan), Latin America and Rest of World Markets 
Independently Analyzed with Annual Sales Figures in US$ 
Million for Years 2011 through 2015 (includes corresponding 
Graph/Chart) II-99 

Table 7: World 10-Year Perspective for Glaucoma by Geographic 
Region - Percentage Breakdown of Dollar Sales for US, Canada, 
Japan, Europe, Asia-Pacific (excluding Japan), Latin America 
and Rest of World Markets for Years 2003, 2008 and 2012 
(includes corresponding Graph/Chart) II-100 

Table 8: World Recent Past, Current and Future Analysis for 
Anti-allergy by Geographic Region - US, Canada, Japan, Europe, 
Asia-Pacific (excluding Japan), Latin America and Rest of 
World Markets Independently Analyzed with Annual Sales Figures 
in US$ Million for Years 2000 through 2010 (includes 
corresponding Graph/Chart) II-101 

Table 9: World Long-term Projections for Anti-Allergy by 
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific 
(excluding Japan), Latin America and Rest of World Markets 
Independently Analyzed with Annual Sales Figures in US$ 
Million for Years 2011 through 2015 (includes corresponding 
Graph/Chart) II-102 

Table 10: World 10-Year Perspective for Anti-allergy by 
Geographic Region - Percentage Breakdown of Dollar Sales for 
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), 
Latin America and Rest of World Markets for Years 2003, 2008 
and 2012 (includes corresponding Graph/Chart) II-103 

Table 11: World Recent Past, Current and Future Analysis for 
Anti-infective by Geographic Region - US, Canada, Japan, 
Europe, Asia-Pacific (excluding Japan), Latin America and Rest 
of World Markets Independently Analyzed with Annual Sales 
Figures in US$ Million for Years 2000 through 2010 (includes 
corresponding Graph/Chart) II-104 

Table 12: World Long-term Projections for Anti-Infective by 
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific 
(excluding Japan), Latin America and Rest of World Markets 
Independently Analyzed with Annual Sales Figures in US$ 
Million for Years 2011 through 2015 (includes corresponding 
Graph/Chart) II-105 

Table 13: World 10-Year Perspective for Anti-infective by 
Geographic Region - Percentage Breakdown of Dollar Sales for 
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), 
Latin America and Rest of World Markets for Years 2003, 2008 
and 2012 (includes corresponding Graph/Chart) II-106 

Table 14: World Recent Past, Current and Future Analysis for 
Dry Eye by Geographic Region - US, Canada, Japan, Europe, 
Asia-Pacific (excluding Japan), Latin America and Rest of 
World Markets Independently Analyzed with Annual Sales Figures 
in US$ Million for Years 2000 through 2010 (includes 
corresponding Graph/Chart) II-107 

Table 15: World Long-term Projections for Dry Eye by 
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific 
(excluding Japan), Latin America and Rest of World Markets 
Independently Analyzed with Annual Sales Figures in US$ 
Million for Years 2011 through 2015 (includes corresponding 
Graph/Chart) II-108 

Table 16: World 10-Year Perspective for Dry Eye by Geographic 
Region - Percentage Breakdown of Dollar Sales for US, Canada, 
Japan, Europe, Asia-Pacific (excluding Japan), Latin America 
and Rest of World Markets for Years 2003, 2008 and 2012 
(includes corresponding Graph/Chart) II-109 

Table 17: World Recent Past, Current and Future Analysis for 
Anti-inflammation by Geographic Region - US, Canada, Japan, 
Europe, Asia-Pacific (excluding Japan), Latin America and Rest 
of World Markets Independently Analyzed with Annual Sales 
Figures in US$ Million for Years 2000 through 2010 (includes 
corresponding Graph/Chart) II-110 

Table 18: World Long-term Projections for Anti-Inflammation by 
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific 
(excluding Japan), Latin America and Rest of World Markets 
Independently Analyzed with Annual Sales Figures in US$ 
Million for Years 2011 through 2015 (includes corresponding 
Graph/Chart) II-111 

Table 19: World 10-Year Perspective for Anti-inflammation by 
Geographic Region - Percentage Breakdown of Dollar Sales for 
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), 
Latin America and Rest of World Markets for Years 2003, 2008 
and 2012 (includes corresponding Graph/Chart) II-112 

Table 20: World Recent Past, Current and Future Analysis for 
Back of Eye by Geographic Region - US, Canada, Japan, Europe, 
Asia-Pacific (excluding Japan), Latin America and Rest of 
World Markets Independently Analyzed with Annual Sales Figures 
in US$ Million for Years 2000 through 2010 (includes 
corresponding Graph/Chart) II-113 

Table 21: World Long-term Projections for Back of Eye by 
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific 
(excluding Japan), Latin America and Rest of World Markets 
Independently Analyzed with Annual Sales Figures in US$ 
Million for Years 2011 through 2015 (includes corresponding 
Graph/Chart) II-114 

Table 22: World 10-Year Perspective for Back of Eye by 
Geographic Region - Percentage Breakdown of Dollar Sales for 
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), 
Latin America and Rest of World Markets for Years 2003, 2008 
and 2012 (includes corresponding Graph/Chart) II-115 

Table 23: World Recent Past, Current and Future Analysis for 
Other Treatment Category by Geographic Region - US, Canada, 
Japan, Europe, Asia-Pacific (excluding Japan), Latin America 
and Rest of World Markets Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2000 through 2010 
(includes corresponding Graph/Chart) II-116 

Table 24: World Long-term Projections for Other Treatment 
Category by Geographic Region - US, Canada, Japan, Europe, 
Asia-Pacific (excluding Japan), Latin America and Rest of 
World Markets Independently Analyzed with Annual Sales Figures 
in US$ Million for Years 2011 through 2015 (includes 
corresponding Graph/Chart) II-117 

Table 25: World 10-Year Perspective for Other Treatment 
Category by Geographic Region - Percentage Breakdown of Dollar 
Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding 
Japan), Latin America and Rest of World Markets for Years 
2003, 2008 and 2012 (includes corresponding Graph/Chart) II-118 

III. MARKET 

1. The United States III-1 
A.Market Analysis III-1 
Outlook III-1 
Emphasis on Greater Awareness About Ophthalmic Disorders III-1 
Growth Drivers In a Capsule III-1 
Impediments to Growth III-1 
Market Fact Sheet III-2 
Glaucoma Market: A Primer III-2 
Awareness Among Patients III-3 
High Costs III-3 
Treatment Patterns Adopted By Doctors III-3 
The All Consuming Issue of Compliance III-3 
Drug Brands & Their Patience Compliance Scores. III-4 
Market Share Statistics III-4 
The New Batting Order III-4 
Table 26: The US Market for Ophthalmic Pharmaceutical 
Drugs (2004-2007): Percentage Market Share Breakdown of 
Leading Players - Alcon Laboratories, Allergan, Novartis 
Pharmaceutical, Pfizer/OSI Pharmaceuticals, Bausch & Lomb 
Pharmaceuticals, and Others (includes corresponding 
Graph/Chart) III-4 

Table 27: Top 10 Brands of Eye/Lens Care in the US: 
Breakdown of Dollar and Unit Sales Through Drug Stores, 
Supermarkets and Discount Stores For the Year Ended 
November 2007 (In US$ 000 and Thousand Units) III-5 

Table 28: Top 5 Eye Care Products in the US: Breakdown of 
Dollar Sales Through Food, Drug and Mass Market Channels 
for the Year Ended July 2007 (In US$ Million) (includes 
corresponding Graph/Chart) III-5 

Table 29: Age-Related Wet Macular Degeneration Market in 
the United States (2004-2006): Percentage Market Share 
Breakdown of Leading Players - QLT Inc/Novartis 
Pharmaceutical Corp, and Eyetech Pharmaceuticals (OSI) / 
Pfizer. III-6 

Table 30: Ocular Allergy Market in the United States 
(2004-2007): Percentage Market Share Breakdown of Leading 
Players - Alcon Laboratories, Novartis Pharmaceutical, 
Bausch & Lomb Pharmaceuticals, Allergan, Santen, and 
Others (includes corresponding Graph/Chart) III-6 

Table 31: Ocular NSAIDs (Topical Non-Steroidal 
Anti-Inflammatory Drugs) Market in the United States (2005 
& 2006): Percentage Market Share Breakdown of Leading 
Players - Allergan, Inc. Novartis Pharmaceutical Corp., 
Alcon Laboratories, Inc., and ISTA Pharmaceuticals 
(includes corresponding Graph/Chart) III-7 

Table 32: Age-Related Macular Degeneration Market in the 
United States (2006, 2009 & 2012): Dollar Sales of Major 
Branded Drugs - Visudyne, Macugen, and Lucentis (In US$ 
Million) (includes corresponding Graph/Chart) III-7 
Age-Related Macular Degeneration Market in the United 
States (2006) - New Brands Expected to hit the Market III-7 
Update On Drugs & Their Manufacturers in the US III-8 
Patent Expirations of Key Ophthalmic Product Brands in the 
United States III-8 
Major Anti-Glaucoma Drugs Available in the United States: 
Year 2006 III-8 
Major Drugs Available in the United States for the 
Treatment of AMD: Year 2005 III-9 
Drugs in the Pipeline for the Treatment of AMD in the 
United States: Year 2005 III-9 
Major Drugs Available in the United States for the Control 
of Dry Eye: Year 2005 III-9 
US Market for Dry Eye: Drugs in the Pipeline Year 2005 III-10 
Companies Actively Involved in Manufacturing Drugs for Dry 
Eye: Year 2005 III-10 
Major Drugs Available in the United States for the 
Treatment of Ocular Allergies: Year 2005 III-10 
US Market for Ocular Allergies: Drugs in the Pipeline: Year 
2005 III-11 
Statistical Findings On Ophthalmic Diseases in the United 
States III-12 
Table 33: Prevalence of Age-Related Macular Degeneration: 
Percentage Breakdown by Wet AMD & Intermediate Dry AMD by 
Age Group for the Year 2005 (includes corresponding 
Graph/Chart) III-12 

Table 34: Prevalence of Age-Related Wet Macular 
Degeneration in the United States for the Years 2006, 2009, 
& 2012 (In Millions of Individuals) (includes corresponding 
Graph/Chart) III-12 

Table 35: Number of Individuals Treated for Wet AMD in the 
United States (In Thousands) for the Years 2006, 2009 & 
2012 (includes corresponding Graph/Chart) III-12 

Table 36: Prevalence of Ocular Hypertension (OHT) in the 
United States for the Years 2006, 2009, & 2011 (In Millions 
of Individuals) (includes corresponding Graph/Chart) III-13 

Table 37: Prevalence of Primary Open Angle Glaucoma (POAG) 
in the United States for the Years 2006, 2009, & 2011 (In 
Millions of Individuals) (includes corresponding 
Graph/Chart) III-13 

Table 38: Prevalence of Normal Tension Glaucoma (NTG) in 
the United States for the Years 2006, 2009, & 2011 (In 
Thousand Individuals) (includes corresponding Graph/Chart) III-13 

Table 39: Prevalence of Exfoliative Glaucoma (EG) in the 
United States for the Years 2006, 2009, & 2011 (In Thousand 
Individuals) (includes corresponding Graph/Chart) III-13 

Table 40: Prevalence of Pigmentary Glaucoma (PG) in the 
United States for the Years 2006, 2009, & 2011 (In Thousand 
Individuals) (includes corresponding Graph/Chart) III-14 

Table 41: Number of Individuals Treated for Glaucoma in the 
United Sates (2006, 2009 and 2011): Breakdown by Type - 
Ocular Hypertension (OHT), Primary Open Angle Glaucoma 
(POAG), Normal Tension Glaucoma (NTG), Pigmentary Glaucoma 
(PG) and Exfoliative Glaucoma (EG) (In 000 Individuals) 
(includes corresponding Graph/Chart) III-14 

Table 42: Prevalence of Ocular Allergy in the United States 
for the Years 2006, 2009, & 2012 (In Millions of 
Individuals) (includes corresponding Graph/Chart) III-14 

Table 43: Number of Individuals Treated for Ocular Allergy 
in the United States (In Million) for the Years 2006, 2009 
& 2012 (includes corresponding Graph/Chart) III-15 

Table 44: Prevalence of Cataract in the United States: 
Percentage Breakdown by Age Group for the Year 2005 
(includes corresponding Graph/Chart) III-15 

Table 45: Prevalence of Cataract in the United States for 
the Years 2006, 2009, & 2012 (In Millions of Individuals) 
(includes corresponding Graph/Chart) III-15 

Table 46: Number of Individuals Treated for Cataract With 
Ocular NSAIDs (Topical Non- Steroidal Anti-Inflammatory 
Drugs) in the United States for the Years 2006, 2009 & 2012 
((In Millions) (includes corresponding Graph/Chart) III-15 

Table 47: Prevalence of Dry Eye in the United States for 
the Years 2006, 2009, & 2012 (In Millions of Individuals) 
(includes corresponding Graph/Chart) III-16 

Table 48: Number of Individuals Treated for Dry Eye in the 
United States (In 000s) for the Years 2006, 2009 & 2012 
(includes corresponding Graph/Chart) III-16 
FDA Approvals III-16 
Product Launches III-21 
Strategic Corporate Developments III-23 
Key Players III-33 
B.Market Analytics III-40 
Table 49: US Recent Past, Current and Future Analysis for 
Ophthalmic Pharmaceutical Drugs by Therapeutic Category - 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-40 

Table 50: US Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-41 

Table 51: US 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category- Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-42 

2. Canada III-43 
A.Market Analysis III-43 
Outlook III-43 
Lack of Awareness: A Key Issue III-43 
Key Players III-43 
Strategic Corporate Developments III-44 
B.Market Analytics III-45 
Table 52: Canadian Recent Past, Current and Future Analysis 
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-45 

Table 53: Canadian Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-46 

Table 54: Canadian 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-47 

3. Japan III-48 
A.Market Analysis III-48 
Outlook III-48 
Growth Drivers III-48 
Market Data Statistics III-48 
Leading Ophthalmic Pharmaceutical Brands In the Market III-48 
Table 55: Japanese Market for Prescription Ophthalmic 
Drugs: Percentage Breakdown by Therapeutic Area - 
Glaucoma, Infection, Corneal Disorder, Ocular Allergy, 
Surgical Preparation, Steroid, Cataract, and Others. 
(includes corresponding Graph/Chart) III-48 
Product Launches III-49 
Strategic Corporate Developments III-49 
Key Players III-50 
B.Market Analytics III-51 
Table 56: Japanese Recent Past, Current and Future Analysis 
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-51 

Table 57: Japanese Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-52 

Table 58: Japanese 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category- Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-53 

4. Europe III-54 
A.Market Analysis III-54 
Outlook III-54 
A Market Primer III-54 
Drug Reimbursement in Europe III-54 
Key Player III-55 
B.Market Analytics III-56 
Table 59: European Recent Past, Current and Future Analysis 
for Ophthalmic Pharmaceutical Drugs by Country/Region - 
France, Germany, Italy, UK, Spain and Rest of Europe Markets 
Independently Analyzed with Annual Sales Figures in US$ 
Million for Years 2000 through 2010 (includes corresponding 
Graph/Chart) III-56 

Table 60: European Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Country/Region - France, Germany, 
Italy, UK, Spain and Rest of Europe Markets Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2011 through 2015 (includes corresponding Graph/Chart) III-57 

Table 61: European 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Country/Region - Percentage 
Breakdown of Dollar Sales for France, Germany, Italy, UK, 
Spain and Rest of Europe Markets for Years 2003, 2008 and 
2012 (includes corresponding Graph/Chart) III-58 

Table 62: European Recent Past, Current and Future Analysis 
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-59 

Table 63: European Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-60 

Table 64: European 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category- Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-61 

4a. France III-62 
A.Market Analysis III-62 
Outlook III-62 
Strategic Corporate Development III-62 
B.Market Analytics III-63 
Table 65: French Recent Past, Current and Future Analysis 
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-63 

Table 66: French Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-64 

Table 67: French 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category- Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-65 

4b. Germany III-66 
Market Analysis III-66 
Table 68: German Recent Past, Current and Future Analysis 
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-66 

Table 69: German Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-67 

Table 70: German 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category- Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-68 

4c. The United Kingdom III-69 
A.Market Analysis III-69 
Outlook III-69 
Key Player III-69 
B.Market Analytics III-69 
Table 71: UK Recent Past, Current and Future Analysis for 
Ophthalmic Pharmaceutical Drugs by Therapeutic Category- 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-69 

Table 72: UK Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-70 

Table 73: UK 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category- Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-71 

4d. Italy III-72 
Market Analysis III-72 
Table 74: Italian Recent Past, Current and Future Analysis 
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-72 

Table 75: Italian Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-73 

Table 76: Italian 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category- Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-74 

4e. Spain III-75 
A.Market Analysis III-75 
Outlook III-75 
How & Why the Health Insurance System in Spain is Conducive? III-75 
Pharmaceutical Reimbursement Reforms in Spain (1996-2002) III-75 
B.Market Analytics III-76 
Table 77: Spanish Recent Past, Current and Future Analysis 
for Ophthalmic Pharmaceutical Drugs by Therapeutic Category- 
Glaucoma, Anti-allergy, Anti-infective, Dry Eye, 
Anti-inflammation, Back of Eye and Others Independently 
Analyzed with Annual Sales Figures in US$ Million for Years 
2000 through 2010 (includes corresponding Graph/Chart) III-76 

Table 78: Spanish Long-term Projections for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category - Glaucoma, 
Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, 
Back of Eye and Others Independently Analyzed with Annual 
Sales Figures in US$ Million for Years 2011 through 2015 
(includes corresponding Graph/Chart) III-77 

Table 79: Spanish 10-Year Perspective for Ophthalmic 
Pharmaceutical Drugs by Therapeutic Category- Percentage 
Breakdown of Dollar Sales for Glaucoma, Anti-allergy, 
Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and 
Others for Years 2003, 2008 and 2012 (includes corresponding 
Graph/Chart) III-78 

4f. Rest of Europe 

To order this report:

World Ophthalmic Pharmaceutical Drugs Market

http://www.reportlinker.com/p090570/World-Ophthalmic-Pharmaceutical-Drugs-Market.html

More market research reports here!

Contact Information